Anthony R White

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8044225/publications.pdf

Version: 2024-02-01

160 papers	14,444 citations	47006 47 h-index	20358 116 g-index
177 all docs	177 docs citations	177 times ranked	22715 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Metalloenzyme-like Activity of Alzheimer's Disease Î²-Amyloid. Journal of Biological Chemistry, 2002, 277, 40302-40308.	3.4	536
3	Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 2003, 422, 80-83.	27.8	457
4	Overexpression of Alzheimer's Disease Amyloid-Î² Opposes the Age-dependent Elevations of Brain Copper and Iron. Journal of Biological Chemistry, 2002, 277, 44670-44676.	3.4	324
5	Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Research, 1999, 842, 439-444.	2.2	279
6	Degradation of the Alzheimer Disease Amyloid Î²-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity. Journal of Biological Chemistry, 2006, 281, 17670-17680.	3.4	267
7	Copper and Zinc Binding Modulates the Aggregation and Neurotoxic Properties of the Prion Peptide PrP106â˜126. Biochemistry, 2001, 40, 8073-8084.	2.5	264
8	Increasing Cu bioavailability inhibits AÎ² oligomers and tau phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 381-386.	7.1	259
9	Structure of the Alzheimer's Disease Amyloid Precursor Protein Copper Binding Domain. Journal of Biological Chemistry, 2003, 278, 17401-17407.	3.4	248
10	Copper complexes as therapeutic agents. Metallomics, 2012, 4, 127-138.	2.4	247
11	Homocysteine potentiates copperâ€•and amyloid beta peptideâ€mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer'sâ€type neurodegenerative pathways. Journal of Neurochemistry, 2001, 76, 1509-1520.	3.9	228
12	Mechanisms of AÎ² mediated neurodegeneration in Alzheimer's disease. International Journal of Biochemistry and Cell Biology, 2008, 40, 181-198.	2.8	220
13	The Alzheimer's Disease Amyloid Precursor Protein Modulates Copper-Induced Toxicity and Oxidative Stress in Primary Neuronal Cultures. Journal of Neuroscience, 1999, 19, 9170-9179.	3.6	213
14	Prion Protein-Deficient Neurons Reveal Lower Glutathione Reductase Activity and Increased Susceptibility to Hydrogen Peroxide Toxicity. American Journal of Pathology, 1999, 155, 1723-1730.	3.8	182
15	Platinum-based inhibitors of amyloid-Î² as therapeutic agents for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6813-6818.	7.1	182
16	Selective Intracellular Release of Copper and Zinc Ions from Bis(thiosemicarbazonato) Complexes Reduces Levels of Alzheimer Disease Amyloid-Î² Peptide. Journal of Biological Chemistry, 2008, 283, 4568-4577.	3.4	177
17	The Alzheimerâ€™s therapeutic PBT2 promotes amyloidâ€Î² degradation and GSK3 phosphorylation via a metal chaperone activity. Journal of Neurochemistry, 2011, 119, 220-230.	3.9	167
18	Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2014, 34, 8021-8031.	3.6	161

#	Article	IF	Citations
19	The Hydrophobic Core Sequence Modulates the Neurotoxic and Secondary Structure Properties of the Prion Peptide 106-126. Journal of Neurochemistry, 2002, 73, 1557-1565.	3.9	152
20	The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinsonâ€™s disease. Journal of Experimental Medicine, 2012, 209, 837-854.	8.5	151
21	Copper as a key regulator of cell signalling pathways. Expert Reviews in Molecular Medicine, 2014, 16, e11.	3.9	139
22	Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochemistry International, 2012, 60, 415-424.	3.8	125
23	Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model. Journal of Biological Chemistry, 2011, 286, 44035-44044.	3.4	123
24	Metal Ionophore Treatment Restores Dendritic Spine Density and Synaptic Protein Levels in a Mouse Model of Alzheimer's Disease. PLoS ONE, 2011, 6, e17669.	2.5	115
25	C-Jun N-terminal kinase controls TDP-43 accumulation in stress granules induced by oxidative stress. Molecular Neurodegeneration, 2011, 6, 57.	10.8	103
26	An impaired mitochondrial electron transport chain increases retention of the hypoxia imaging agent diacetylbis(4-methylthiosemicarbazonato)copper ^{II}. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 47-52.	7.1	101
27	Gene knockout of amyloid precursor protein and amyloid precursorâ€like proteinâ€2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. Journal of Neurochemistry, 2004, 91, 423-428.	3.9	100
28	Survival of Cultured Neurons from Amyloid Precursor Protein Knock-Out Mice against Alzheimerâ€™s Amyloid-Î² Toxicity and Oxidative Stress. Journal of Neuroscience, 1998, 18, 6207-6217.	3.6	90
29	Conjugation of Transferrin to Azideâ€Modified CdSe/ZnS Coreâ€“Shell Quantum Dots using Cyclooctyne Click Chemistry. Angewandte Chemie - International Edition, 2012, 51, 10523-10527.	13.8	87
30	Restored degradation of the Alzheimerâ€™s amyloidâ€Î² peptide by targeting amyloid formation. Journal of Neurochemistry, 2009, 108, 1198-1207.	3.9	85
31	Contrasting, Species-Dependent Modulation of Copper-Mediated Neurotoxicity by the Alzheimer's Disease Amyloid Precursor Protein. Journal of Neuroscience, 2002, 22, 365-376.	3.6	83
32	Therapeutic effects of Cu^{II}(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 586-590.	1.7	82
33	Exacerbation of Copper Toxicity in Primary Neuronal Cultures Depleted of Cellular Glutathione. Journal of Neurochemistry, 2008, 72, 2092-2098.	3.9	79
34	Mechanisms Controlling the Cellular Accumulation of Copper Bis(thiosemicarbazonato) Complexes. Inorganic Chemistry, 2011, 50, 9594-9605.	4.0	76
35	Copper and Alzheimerâ€™s Disease. Advances in Neurobiology, 2017, 18, 199-216.	1.8	71
36	Bis (thiosemicarbazonato) Cu-64 Complexes for Positron Emission Tomography Imaging of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 49-55.	2.6	70

#	Article	IF	Citations
37	Blood-Borne Amyloid-Î² Dimer Correlates with Clinical Markers of Alzheimer's Disease. Journal of Neuroscience, 2010, 30, 6315-6322.	3.6	70
38	CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Scientific Reports, 2017, 7, 42292.	3.3	70
39	Sublethal Concentrations of Prion Peptide PrP106â€“126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons. Neurobiology of Disease, 2001, 8, 299-316.	4.4	66
40	Correlative studies support lipid peroxidation is linked to PrPres propagation as an early primary pathogenic event in prion disease. Brain Research Bulletin, 2006, 68, 346-354.	3.0	66
41	The modulation of metal bioâ€availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS Journal, 2007, 274, 3775-3783.	4.7	66
42	Neurotoxicity from glutathione depletion is dependent on extracellular trace copper. Journal of Neuroscience Research, 2003, 71, 889-897.	2.9	63
43	Altered Brain Endothelial Cell Phenotype from a Familial Alzheimer Mutation and Its Potential Implications for Amyloid Clearance and Drug Delivery. Stem Cell Reports, 2020, 14, 924-939.	4.8	63
44	TDP-43 mutations causing amyotrophic lateral sclerosis are associated with altered expression of RNA-binding protein hnRNP K and affect the Nrf2 antioxidant pathway. Human Molecular Genetics, 2017, 26, 1732-1746.	2.9	62
45	Differential modulation of Alzheimer's disease amyloid Î²-peptide accumulation by diverse classes of metal ligands. Biochemical Journal, 2007, 407, 435-450.	3.7	58
46	Mild Oxidative Stress Induces Redistribution of BACE1 in Non-Apoptotic Conditions and Promotes the Amyloidogenic Processing of Alzheimerâ€™s Disease Amyloid Precursor Protein. PLoS ONE, 2013, 8, e61246.	2.5	55
47	Amyloidogenicity and neurotoxicity of peptides corresponding to the helical regions of PrPC. Journal of Neuroscience Research, 2000, 62, 293-301.	2.9	53
48	Metal-deficient SOD1 in amyotrophic lateral sclerosis. Journal of Molecular Medicine, 2015, 93, 481-487.	3.9	51
49	Evidence for a Copper-Binding Superfamily of the Amyloid Precursor Proteinâ€. Biochemistry, 2002, 41, 9310-9320.	2.5	50
50	Zinc induces depletion and aggregation of endogenous TDP-43. Free Radical Biology and Medicine, 2010, 48, 1152-1161.	2.9	50
51	Kinase Inhibitor Screening Identifies Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 as Potential Modulators of TDP-43 Cytosolic Accumulation during Cell Stress. PLoS ONE, 2013, 8, e67433.	2.5	50
52	Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43. Human Molecular Genetics, 2015, 24, 1655-1669.	2.9	48
53	Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. Journal of Neuroscience Research, 2001, 65, 565-572.	2.9	47
54	Neuroinflammation and Copper in Alzheimerâ€™s Disease. International Journal of Alzheimer's Disease, 2013, 2013, 1-12.	2.0	47

#	Article	IF	Citations
55	Targeting Glycogen Synthase Kinase-3Î²for Therapeutic Benefit against Oxidative Stress in Alzheimer's Disease: Involvement of the Nrf2-ARE Pathway. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	2.0	46
56	Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease. Neurochemistry International, 2018, 117, 126-138.	3.8	46
57	In vitro gamma-secretase cleavage of the Alzheimer's amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc. FEBS Journal, 2005, 272, 5544-5557.	4.7	45
58	Inhibition of TDP-43 Accumulation by Bis(thiosemicarbazonato)-Copper Complexes. PLoS ONE, 2012, 7, e42277.	2.5	44
59	The challenges of using a copper fluorescent sensor (CS1) to track intracellular distributions of copper in neuronal and glial cells. Chemical Science, 2012, 3, 2748.	7.4	43
60	ALS monocyte-derived microglia-like cells reveal cytoplasmic TDP-43 accumulation, DNA damage, and cell-specific impairment of phagocytosis associated with disease progression. Journal of Neuroinflammation, 2022, 19, 58.	7.2	43
61	Iron inhibits neurotoxicity induced by trace copper and biological reductants. Journal of Biological Inorganic Chemistry, 2004, 9, 269-280.	2.6	42
62	The Copper bis(thiosemicarbazone) Complex CuII(atsm) Is Protective Against Cerebral Ischemia Through Modulation of the Inflammatory Milieu. Neurotherapeutics, 2017, 14, 519-532.	4.4	42
63	A domain level interaction network of amyloid precursor protein and AÎ² of Alzheimer's disease. Proteomics, 2010, 10, 2377-2395.	2.2	41
64	Phosphorylation of Amyloid Precursor Protein at Threonine 668 Is Essential for Its Copper-responsive Trafficking in SH-SY5Y Neuroblastoma Cells. Journal of Biological Chemistry, 2014, 289, 11007-11019.	3.4	41
65	Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Human Molecular Genetics, 2014, 23, 4051-4063.	2.9	41
66	Metal homeostasis in Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2006, 6, 711-722.	2.8	39
67	Copper(<scp>ii</scp>) complexes of hybrid hydroxyquinoline-thiosemicarbazone ligands: GSK3Î² inhibition due to intracellular delivery of copper. Dalton Transactions, 2011, 40, 1338-1347.	3.3	39
68	Profiling the iron, copper and zinc content in primary neuron and astrocyte cultures by rapid online quantitative size exclusion chromatography-inductively coupled plasma-mass spectrometry. Metallomics, 2013, 5, 1656.	2.4	39
69	Neuroprotective Copper Bis(thiosemicarbazonato) Complexes Promote Neurite Elongation. PLoS ONE, 2014, 9, e90070.	2.5	39
70	The role of metals in modulating metalloprotease activity in the AD brain. European Biophysics Journal, 2008, 37, 315-321.	2.2	38
71	X-ray fluorescence imaging reveals subcellular biometal disturbances in a childhood neurodegenerative disorder. Chemical Science, 2014, 5, 2503-2516.	7.4	38
72	Circumventing the Crabtree Effect: A method to induce lactate consumption and increase oxidative phosphorylation in cell culture. International Journal of Biochemistry and Cell Biology, 2016, 79, 128-138.	2.8	38

#	Article	IF	Citations
73	Pyrrolidine dithiocarbamate activates the Nrf2 pathway in astrocytes. Journal of Neuroinflammation, 2016, 13, 49.	7.2	38
74	Overexpression of AÎ² is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. Aging Cell, 2006, 5, 153-165.	6.7	37
75	Sustained Activation of Glial Cell Epidermal Growth Factor Receptor by Bis(thiosemicarbazonato) Metal Complexes Is Associated with Inhibition of Protein Tyrosine Phosphatase Activity. Journal of Medicinal Chemistry, 2009, 52, 6606-6620.	6.4	37
76	Manganese chelation therapy extends survival in a mouse model of M1000 prion disease. Journal of Neurochemistry, 2010, 114, 440-451.	3.9	37
77	Increased metal content in the TDP-43A315T transgenic mouse model of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Frontiers in Aging Neuroscience, 2014, 6, 15.	3.4	37
78	Deregulation of subcellular biometal homeostasis through loss of the metal transporter, Zip7, in a childhood neurodegenerative disorder. Acta Neuropathologica Communications, 2014, 2, 25.	5.2	37
79	Chronic stress and <scp>A</scp>lzheimer's disease: theâ€‰interplay between the hypothalamicâ€“pituitaryâ€“adrenal axis, genetics and microglia. Biological Reviews, 2021, 96, 2209-2228.	10.4	37
80	Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News and Perspectives, 2006, 19, 469.	1.5	37
81	Copper and zinc bis(thiosemicarbazonato) complexes with a fluorescent tag: synthesis, radiolabelling with copper-64, cell uptake and fluorescence studies. Journal of Biological Inorganic Chemistry, 2010, 15, 225-235.	2.6	36
82	Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. CNS Drugs, 2016, 30, 227-243.	5.9	36
83	Urban air particulate matter induces mitochondrial dysfunction in human olfactory mucosal cells. Particle and Fibre Toxicology, 2020, 17, 18.	6.2	36
84	Familial Prion Disease Mutation Alters the Secondary Structure of Recombinant Mouse Prion Protein:Â Implications for the Mechanism of Prion Formationâ€. Biochemistry, 1999, 38, 3280-3284.	2.5	35
85	Amyloid Î². International Journal of Biochemistry and Cell Biology, 1999, 31, 885-889.	2.8	34
86	Immunotherapy as a therapeutic treatment for neurodegenerative disorders. Journal of Neurochemistry, 2004, 87, 801-808.	3.9	33
87	Copper Imbalance in Alzheimerâ€™s Disease and Its Link with the Amyloid Hypothesis: Towards a Combined Clinical, Chemical, and Genetic Etiology. Journal of Alzheimer's Disease, 2021, 83, 23-41.	2.6	31
88	Diverse fibrillar peptides directly bind the Alzheimerâ€™s amyloid precursor protein and amyloid precursor-like protein 2 resulting in cellular accumulation. Brain Research, 2003, 966, 231-244.	2.2	30
89	Therapeutic Treatment of Alzheimers Disease Using Metal Complexing Agents. Recent Patents on CNS Drug Discovery, 2007, 2, 180-187.	0.9	30
90	Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimerâ€™s disease. Molecular BioSystems, 2009, 5, 134-142.	2.9	30

#	Article	IF	Citations
91	Editorial: Metals and neurodegeneration: restoring the balance. Frontiers in Aging Neuroscience, 2015, 7, 127.	3.4	30
92	HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, prevents ischemia-induced neuronal damage. Brain, Behavior, and Immunity, 2018, 73, 670-681.	4.1	29
93	Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor Î± Release from Macrophages. Journal of Pharmacology and Experimental Therapeutics, 2008, 324, 360-367.	2.5	28
94	ZnII(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism. Neurobiology of Disease, 2015, 81, 20-24.	4.4	28
95	Endogenous Cu in the central nervous system fails to satiate the elevated requirement for Cu in a mutant SOD1 mouse model of ALS. Metallomics, 2016, 8, 1002-1011.	2.4	28
96	Increased Zinc and Manganese in Parallel with Neurodegeneration, Synaptic Protein Changes and Activation of Akt/GSK3 Signaling in Ovine CLN6 Neuronal Ceroid Lipofuscinosis. PLoS ONE, 2013, 8, e58644.	2.5	28
97	Serum matrix metalloproteinase-9 activity is dysregulated with disease progression in the mutant SOD1 transgenic mice. Neuromuscular Disorders, 2010, 20, 260-266.	0.6	27
98	Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis. Biology Open, 2013, 2, 635-646.	1.2	27
99	Deregulation of biometal homeostasis: the missing link for neuronal ceroid lipofuscinoses?. Metallomics, 2014, 6, 932-943.	2.4	27
100	Mitochondrial metals as a potential therapeutic target in neurodegeneration. British Journal of Pharmacology, 2014, 171, 2159-2173.	5.4	27
101	Failure of Autophagyâ€“Lysosomal Pathways in Rod Photoreceptors Causes the Early Retinal Degeneration Phenotype Observed inCln6^{nclf}Mice. , 2018, 59, 5082.		27
102	3D human brain cell models: New frontiers in disease understanding and drug discovery for neurodegenerative diseases. Neurochemistry International, 2018, 120, 191-199.	3.8	27
103	Neuron-astrocyte transmitophagy is altered in Alzheimer's disease. Neurobiology of Disease, 2022, 170, 105753.	4.4	27
104	Activation of epidermal growth factor receptor by metal-ligand complexes decreases levels of extracellular amyloid beta peptide. International Journal of Biochemistry and Cell Biology, 2008, 40, 1901-1917.	2.8	26
105	Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease. Free Radical Biology and Medicine, 2013, 60, 147-156.	2.9	26
106	CuII(atsm) Attenuates Neuroinflammation. Frontiers in Neuroscience, 2018, 12, 668.	2.8	26
107	Acetylcholinesterase is increased in mouse neuronal and astrocyte cultures after treatment with Î²-amyloid peptides. Brain Research, 2003, 965, 283-286.	2.2	25
108	Restoration of intestinal function in an MPTP model of Parkinsonâ€™s Disease. Scientific Reports, 2016, 6, 30269.	3.3	25

#	Article	IF	Citations
109	Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups. Inorganic Chemistry, 2019, 58, 4540-4552.	4.0	25
110	Clioquinol inhibits peroxide-mediated toxicity through up-regulation of phosphoinositol-3-kinase and inhibition of p53 activity. International Journal of Biochemistry and Cell Biology, 2008, 40, 1030-1042.	2.8	24
111	Intracellular Distribution of Fluorescent Copper and Zinc Bis(thiosemicarbazonato) Complexes Measured with Fluorescence Lifetime Spectroscopy. Inorganic Chemistry, 2015, 54, 9556-9567.	4.0	24
112	Toward Hypoxia-Selective Rhenium and Technetium Tricarbonyl Complexes. Inorganic Chemistry, 2015, 54, 9594-9610.	4.0	24
113	If Human Brain Organoids Are the Answer to Understanding Dementia, What Are the Questions?. Neuroscientist, 2020, 26, 438-454.	3.5	23
114	Enhancing survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant TDP-43 mice. Human Molecular Genetics, 2016, 25, 4080-4093.	2.9	22
115	Neurotoxicity from glutathione depletion is mediated by Cu-dependent p53 activation. Free Radical Biology and Medicine, 2008, 44, 44-55.	2.9	21
116	Effect of Metal Chelators onÎ³-Secretase Indicates That Calcium and Magnesium Ions Facilitate Cleavage of Alzheimer Amyloid Precursor Substrate. International Journal of Alzheimer's Disease, 2011, 2011, 1-10.	2.0	21
117	Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex. BioMetals, 2011, 24, 117-133.	4.1	21
118	Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux. Journal of Medicinal Chemistry, 2018, 61, 711-723.	6.4	21
119	Protein Labelling with Versatile Phosphorescent Metal Complexes for Live Cell Luminescence Imaging. Chemistry - A European Journal, 2015, 21, 14146-14155.	3.3	20
120	The potential impact of bushfire smoke on brain health. Neurochemistry International, 2020, 139, 104796.	3.8	20
121	Single-Cell RNA-Seq Analysis of Olfactory Mucosal Cells of Alzheimerâ€™s Disease Patients. Cells, 2022, 11, 676.	4.1	20
122	Alzheimerâ€™s disease amyloid beta and prion protein amyloidogenic peptides promote macrophage survival, DNA synthesis and enhanced proliferative response to CSF-1 (M-CSF). Brain Research, 2002, 940, 49-54.	2.2	17
123	Subcellular localization of a fluorescent derivative of CuII(atsm) offers insight into the neuroprotective action of CuII(atsm). Metallomics, 2011, 3, 1280.	2.4	17
124	Integrative Network-Based Analysis Reveals Gene Networks and Novel Drug Repositioning Candidates for Alzheimer Disease. Neurology: Genetics, 2021, 7, e622.	1.9	17
125	â€œFocused Ultrasound-mediated Drug Delivery in Humans â€“ a Path Towards Translation in Neurodegenerative Diseasesâ€• Pharmaceutical Research, 2022, 39, 427-439.	3.5	16
126	The accumulation of enzymatically inactive cuproenzymes is a CNS-specific phenomenon of the SOD1G37R mouse model of ALS and can be restored by overexpressing the human copper transporter hCTR1. Experimental Neurology, 2018, 307, 118-128.	4.1	15

#	Article	IF	Citations
127	Olfactory cell cultures to investigate health effects of air pollution exposure: Implications for neurodegeneration. Neurochemistry International, 2020, 136, 104729.	3.8	15
128	Potential Impacts of Extreme Heat and Bushfires on Dementia. Journal of Alzheimer's Disease, 2021, 79, 969-978.	2.6	15
129	Loss of CLN5 causes altered neurogenesis in a childhood neurodegenerative disorder. DMM Disease Models and Mechanisms, 2017, 10, 1089-1100.	2.4	14
130	Peptide-Oligonucleotide Hybrids in Antisense Therapy. Mini-Reviews in Medicinal Chemistry, 2005, 5, 41-55.	2.4	12
131	Water-soluble Bis(thiosemicarbazonato)copper(II) Complexes. Australian Journal of Chemistry, 2011, 64, 244.	0.9	12
132	Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimerâ€™s Disease. Pharmaceutical Research, 2017, 34, 2652-2662.	3.5	11
133	The synthesis and spectroscopic analysis of the neurotoxic prion peptide 106â€“126: Comparative use of manual Boc and Fmoc chemistry. International Journal of Peptide Research and Therapeutics, 1999, 6, 129-134.	0.1	10
134	Metals and Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-2.	2.0	10
135	Copper modulates the large dense core vesicle secretory pathway in PC12 cells. Metallomics, 2013, 5, 700.	2.4	10
136	Biometals in rare neurodegenerative disorders of childhood. Frontiers in Aging Neuroscience, 2013, 5, 14.	3.4	10
137	Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinsonâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1698-1704.	2.2	10
138	Regular Physical Exercise Modulates Iron Homeostasis in the 5xFAD Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 8715.	4.1	10
139	Investigating copperâ€regulated protein expression in Menkes fibroblasts using antibody microarrays. Proteomics, 2008, 8, 1819-1831.	2.2	8
140	Neurotoxicity of Prion Peptides on Cultured Cerebellar Neurons. Methods in Molecular Biology, 2008, 459, 83-96.	0.9	6
141	Recent Advances in Microglia Modelling to Address Translational Outcomes in Neurodegenerative Diseases. Cells, 2022, 11, 1662.	4.1	6
142	A potential copper-regulatory role for cytosolic expression of the DNA repair protein XRCC5. Free Radical Biology and Medicine, 2011, 51, 2060-2072.	2.9	5
143	Oxidative stress and neurodegeneration. Neurochemistry International, 2013, 62, 521.	3.8	5
144	X-ray fluorescence microscopic measurement of elemental distribution in the mouse retina with age. Metallomics, 2016, 8, 1110-1121.	2.4	5

#	Article	IF	Citations
145	Increased iron content in the heart of the Fmr1 knockout mouse. BioMetals, 2021, 34, 947-954.	4.1	5
146	Membraneâ€targeted strategies for modulating APP and Aî²â€mediated toxicity. Journal of Cellular and Molecular Medicine, 2009, 13, 249-261.	3.6	4
147	Immunotherapeutic approaches in prion disease: progress, challenges and potential directions. Therapeutic Delivery, 2013, 4, 615-628.	2.2	4
148	A greater focus on metals in biomedicine and neuroscience is needed. BMC Pharmacology & Toxicology, 2016, 17, 53.	2.4	4
149	Phosphorylation of hnRNP K controls cytosolic accumulation of TDP-43. Molecular Neurodegeneration, 2013, 8, P46.	10.8	3
150	Typeâ€‰interferons in Parkinson's disease: innate inflammatory response drives fate of neurons in model of degenerative brain disorder. Journal of Neurochemistry, 2017, 141, 9-11.	3.9	3
151	Modeling the Bloodâ€“Brain Barrier to Understand Drug Delivery in Alzheimerâ€™s Disease. , 0, , 117-134.		3
152	Biometal Dyshomeostasis in Olfactory Mucosa of Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 4123.	4.1	3
153	Metal Complexing Agents for the Treatment of Alzheimer's Disease. , 2007, , 107-136.		2
154	Abnormal Function of Metalloproteins Underlies Most Neurodegenerative Diseases. , 2017, , 415-438.		2
155	Editorial: Air pollution and brain health. Neurochemistry International, 2020, 141, 104900.	3.8	2
156	Isolation and growth of a cytopathic agent from multiple sclerosis brain tissue. Journal of NeuroVirology, 2002, 8, 111-121.	2.1	1
157	Heterogeneous nuclear ribonucleoproteins in amyotrophic â€˜lateral sclerosis: what do we know?. Future Neurology, 2014, 9, 173-185.	0.5	1
158	Copper and Molecular Aspects of Cell Signaling. , 2017, , 85-99.		1
159	Title is missing!. International Journal of Peptide Research and Therapeutics, 1999, 6, 129-134.	0.1	0
160	Therapeutic Treatment of Alzheimer's Disease Using Metal Complexing Agents. , 2012, , 106-122.		0